NAT2 and prostate cancer: We found that the factors associated with a significantly increased risk of prostate cancer were the NAT2 slow acetylator phenotype (OR, 1.65; 95% CI, 1.04–2.61), the CYP1A1 GG genotype (OR, 1.76; 95% CI, 1.08–2.87), the CYP1A1 GA + GG genotype (OR, 1.27; 95% CI, 1.02–1.59), the CYP1A2 CA genotype (OR, 1.43; 95% CI, 1.01–2.03), the CYP1A2 AA genotype (OR, 1.44; 95% CI, 1.00–2.06), and the CYP1A2 CA + AA genotype (OR, 1.43; 95% CI, 1.03–2.00).